Organized and hosted by the Children's Tumor Foundation (CTF), the Neurofibromatosis (NF) conference is the premier annual gathering for clinicians and researchers interested in neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN).
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The Neurofibromatosis (NF) conference is the premier annual gathering of the NF professional community. This international meeting is organized and hosted by the Children's Tumor Foundation (CTF) and aims to bring the most up-to-date clinical and basic research findings to the NF community, foster critical debate, generate new ideas, and promote collaboration and synergies among participants. There is also room to introduce experimental approaches, technology, and ideas from outside NF via keynote addresses from experts in other fields and by attracting scientists from outside the NF community to expand collaborative opportunities. The promotion and consolidation of young scientists and clinicians engaged in a broad range of disciplines related to NF is also important to foster the development of emerging investigators in the field.
The 2016 edition took place in Austin, TX and constituted a blend of clinical and basic aspects of NF research, trying to maintain the difficult equilibrium between both worlds that need to interface to move the field forward. Most sessions were designed to be "bench to bedside" with both a basic and clinical research focus. Technical aspects such as the incorporation of next generation sequencing (NGS), cellular pathophysiology, and the development of new preclinical model systems were mixed with the impact of novel imaging techniques and novel therapeutic approaches. NF1, NF2, and SWN were each addressed as were various complications including musculoskeletal abnormalities of NF1, central nervous system tumors in NF, and peripheral nerve sheath tumors. There was also an exploration of psychological, social, and biological factors to build new models of NF management. In addition, updates from various NF consortia and two sessions focused on issues in clinical management were included. While the keynote speakers were once again primarily from investigators outside the field, a new initiative, "Perspectives Talks," was launched at the 2016 conference. The latter talks were from experts within the NF field, on topics related to and part of particular sessions, and included not just an update on the speaker's research but also their thoughts on new directions in the field.
highlighted "the Resilience Project," a retrospective study on 100 childhood diseases, as well as early examples in NF (CTF's Synodos projects) in which clinicians, bench scientists, and computational analysts are harnessing clinical, functional, and "omics" data together to identify not just drivers of disease but also modulators of disease outcome. He finished the keynote by noting the importance of empowering and partnering with patients in research, such as the development of phone apps to measure patient outcomes in clinical trials.
In another keynote address, Dr. Crystal Mackall (Stanford, CA) reviewed emerging immunotherapy strategies and how they might be harnessed for NF-related tumors. She cautioned that while checkpoint inhibitor therapy has induced durable responses in a wide range of cancers, at present, it is believed that tumors with low mutational burden are less likely to respond. Thus, while this approach may bear fruition in malignant peripheral nerve sheath tumor (MPNST) of high-grade glioma, it is less likely to work with common NF-associated low-grade tumors, such as low-grade glioma, plexiform neurofibroma (PNF), or vestibular schwannoma. In addition, the toxicity of checkpoint inhibitors and chimeric antigen receptor T-cell strategies must be weighed when targeting low-grade tumors. Perhaps if appropriate antigens were identified, vaccine approaches might be effective in preventing transformation of nerve sheath tumors from low to high grade.
Dr. David Solit's (Memorial Sloan Kettering Cancer Center, NY)
keynote address centered on the changing application of NGS in the clinical oncology setting. Understanding which part of the genome is clinically actionable is helping to transform oncology trials. Traditionally, trials have been based on obtaining statistically significant benefits of genetically unselected populations, and now trials can identify unrecognized biomarkers of response to agents in a limited number of patients.
Dr. Solit explained the Memorial Sloan Kettering-Integrated Mutation
Profiling of Actionable Cancer Targets approach to enable precision oncology in patients with solid tumors, and the basket study schema, in which treatments are not focused on histologically similar types of cancer but rather on heterogeneous tumors that have the same altered/ mutated pathway(s).
Human pluripotent stem cells have great potential in many aspects of medicine, from tissue engineering to disease modeling. However, not many laboratories have expertise in using induced pluripotent stem cells (iPSCs) to generate neural crest stem cells, from which many of the cell types affected in NF derive. One such laboratory is led by Dr.
Stephen Dalton (University of Georgia, GA), who gave a keynote presentation on how to use iPSCs to understand NC development and dis- in a keynote speech suggested potential new approaches to target RAS signaling. He described the role of SPRED1 in recruiting neurofibromin to RAS. Guanosine triphosphate (GTP), where the complex inactivates RAS by converting it to RAS-GDP. In the absence of neurofibromin, RAS-GTP accumulates and drives downstream mitogen-activated protein kinase (MAPK) pathway signaling. Thus, a more complete understanding of this protein complex may help identify novel therapeutic targets. He also noted that RAS-GTP dimers activate the MAPK pathway, suggesting that disruption of dimerization may be an approach to prevent RAS signaling. In addition, he identified novel Kirsten rat sarcoma (KRAS) effector pathways. KRAS binds to calmodulin and inhibits calmodulin-dependent kinase leading to a stem cell-like phenotype, which is in part promoted by the secretion of LIF (leukemia inhibitory factor), which is expressed in high levels in KRAS mutant cells. Thus, targeting LIF may reduce stemness and be a novel way to target RAS. LZTR1, and NF2 in the blood. Mutations were identified in LZTR1 in 5 patients, SMARCB1 in 9 patients, and no mutation was found in 18 patients. SMARCB1 and LZTR1 mutated schwannomatosis patients did not differ in the number of schwannomas developed, but in the latter group the pain level was higher.
Dr. Kristine Vogel (UT Health Science Center, San Antonio, TX) presented studies linking DNA damage repair genes and NF1 disease severity. Characterization of NF1 loss-of-heterozygosity and somatic mutation spectra in cutaneous neurofibromas raised the possibility that genetic differences in DNA damage repair capacity (influencing somatic mutation rates) might act as modifiers of disease severity. S100 positive Schwann cell (SC) cultures were established from cutaneous neurofibromas removed from four adults with NF1. SCs were exposed to doxorubicin, and DNA damage sensitivity and repair efficiency was 
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MPNST is a leading cause of mortality in patients with NF1, and outcomes have not improved over the last several decades. This session, chaired by Drs. AeRang Kim and Lu Le, focused on the substantial progress that has been made in understanding the pathogenesis of PNF, atypical neurofibromas (ANF), and MPNST. In a Perspectives talk, Dr.
Brigitte Widemann (National Institutes of Health, Bethesda, MD) presented an overview of the field and highlighted the use of longitudinal and whole body MRI with volumetric analysis to understand the natural history of PNF Gutmann, Blakeley, Korf, & Packer, 2013; Solomon, Warren, Dombi, Patronas, & Widemann, 2004) . She also described that distinct nodular lesions within PNF may be precursor lesions to MPNST (Meany et al., 2013) . have identified deletion of the CDKN2A/2B locus as the most frequent genetic event distinctive from PNF in ANF (Beert et al., 2011; Nielsen et al., 1999) . His group performed whole exome sequencing in 16 ANF and 4 MPNST matched with germline DNA obtained from 14 and 4 unrelated NF1 patients, respectively. It appears the PNF-to-ANF transition is predominantly driven by heterozygous deletion of the CDKN2A/ 2B locus, but no PRC2 mutations are identified in ANF. The somatic mutation burden in the ANF is relatively low and comparable to that in PNF, however the level of genomic instability is elevated in the ANF.
Two novel somatic mutations in PRC2 genes were found in two MPNST and also in a potential novel driver gene coding for a histone H4-specific acetyltransferase. A subset of patients with NF1 can present with unilateral anterolateral bowing of the tibia with cortical thickening and medullary canal narrowing radiographically, which is often followed by fracture and pseudoarthrosis. Past studies have documented somatic NF1 "second hits" in pseudoarthrosis tissue samples, providing some evidence of the underlying etiology (Paria et al., 2014) . However, little is known about the architecture and bone quality of the bowed tibia prior to fracture. 
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Kalamarides, 2017; Goutagny et al., 2015) . Further, they showed that the dual mTORC1/mTORC2 inhibitor AZD2014 was more effective than rapamycin in blocking proliferation of meningioma cells. They have now undertaken studies to define the adaptive kinome response in isogenic NF2-expressing and NF2-null human arachnoidal cells treated with either rapamycin or AZD2014, and kinases preferentially induced by AZD2014 or rapamycin were identified (Beauchamp et al., 2015) . Consistent activation of erythropoietin-producing human hepatocellular (EPH) receptor family members was found in both arachnoidal and meningioma cells with NF2 loss. Based on these observations, in vitro combination treatment with AZD2014 and dasatinib, a potent inhibitor of many of the EPH family members, was tested and synergy between these two drugs found to effectively inhibit meningioma cell growth. Defining adaptive kinome response has the potential to reveal effective combination therapies and will have direct impact on NF2 research as well as patient care. Dr. Matthias Karajannis presented a retrospective review of patients with NF2 and progressive vestibular schwannomas treated on a Phase II clinical trial with lapatinib, a dual EGFR/ErbB2 inhibitor (Karajannis et al., 2012) . The data suggested that lapatinib has modest growth-inhibitory effects on meningiomas in NF2 patients, but prospective studies of lapatinib for NF2 patients with progressive meningiomas may be warranted. 
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| P R ES EN T A N D F U TU R E I M PA CT OF NOV E L I M A GI N G I N TH E M A NA GE M EN T OF NF
In this session organized by Drs. Peter de Blank and Gordon Harris, four novel imaging approaches with potential impact on the assessment and management of subjects with neurofibromatosis were presented. These novel approaches go beyond the standard clinical assessments of brain structure to view parameters of neural microstructure and function that may be disrupted in subjects with NF. Dr. Donald Mabbott (Hospital for Sick Children, Toronto, Canada) discussed white matter microstructure using diffusion imaging (tensor and kurtosis) and magnetization transfer imaging, and how this may relate to cognition. Among 32 children with low-grade glioma treated without radiation, compromise of supratentorial white matter mediated the effect of treatment on intelligence quotient, suggesting that brain tumor therapies affect cognition by damaging white matter. Greater white matter damage was seen in five children with NF1 (Liu et al., 2015) . However, exercise may help moderate the neurotoxic effect of cranial radiation. In an ongoing study, children exposed to cranial radiation participate in a 12-week exercise regimen to determine the effect of exercise on white matter integrity and cognitive impairment. Initial results demonstrate the feasibility of this approach. Dr. Timothy Roberts (Children's Hospital of Philadelphia, PA) discussed strategies to use magnetoencephalography (MEG) in the context of multimodal imaging to establish biomarkers for autistic spectrum disorder (ASD), which occurs with increased frequency in children with NF1. MEG captures the electrical activity of neurons by measuring the magnetic fields they produce over time. Latency prolongation in the auditory evoked response can be seen in children with ASD with or without language and speech deficits, and may be a useful predictive biomarker of ASD (Roberts et al., 2010) . Evidence from diffusion tensor imaging and magnetic resonance spectroscopy experiments provide further evidence for a biological basis for latency prolongation in auditory processing.
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Jennifer Janusz (Children's Hospital Colorado, Denver, CO) laid the framework for this session, chaired by Drs. Staci Martin and Nicole Ullrich, by introducing the environmental and family variables that exist when caring for individuals with NF and the potential interventions that are available. The impact of illness on family and the impact of family on illness were defined, and a pediatric psychology health model was presented (Kazak et al., 2007) . This model posits a tiered approach starting with broad-based and universal approaches for psycho-education, then moving to targeted interventions for specific symptoms, and lastly to intensified psychosocial services for specific issues using behavioral health specialists such as cognitive behavioral therapy and family problem solving interventions. The Ana-Maria Vranceanu (Massachusetts General Hospital, Boston, MA) discussed her work related to a mind-body treatment that she adapted for patients with NF1, NF2, and schwannomatosis using qualitative information collected via focus groups. This intervention includes eight weekly sessions delivered via live video using Skype in small groups. Individuals are randomized to receive either "active training," which includes resiliency training, adaptive thinking, and positive psychology, versus "inactive training," which includes educational information on stress, nutrition, exercise, and medical care.
The initial trial in adults was feasible with a high level of satisfaction among participants regardless of conditions (active vs. inactive). In addition, "active training" resulted in improved quality of life and reduced anxiety and pain beyond that of "inactive training." Improvements were statistically significant, clinically meaningful, and durable. Dr. Vranceanu also discussed her current projects testing this mind-body treatment adapted for adolescents and adults with NF2 who are deaf.
Taylor Smith (California Polytechnic State University, San Luis Obispo, CA; Rhode Island Hospital) presented a collaboration with Children's National Medical Center (Washington, DC) on coping in parents of children with NF1. Prior studies have demonstrated higher levels of parental stress among parents of children with NF1 (Esposito et al., 2014) , and that the severity of disease in the child is associated with increased parental psychiatric symptoms, increased family conflict and less social support (Reiter-Purtill et al., 2008) . Data were collected as part of a larger project which developed an online parenting resource/ intervention. They found that learning difficulties and NF1 severity are associated with greater parenting stress and distress and that this relationship is partially mediated by parental coping strategy use. Limitations included the lack of control group and small numbers of familial NF1 cases. Results support the inclusion of mental health screening measures for parents, and parental cognitions and coping as targets for parental intervention.
Nicole Ullrich (Boston Children's Hospital, MA) presented a pilot study that uses social media (with restricted access as a community of shared experience) to improve quality of life and medical outcomes in adolescents with NF1 and their parents. Participants created a video intervention/prevention assessment about living with or parenting a child with NF1 and then quality of life and disease severity were assessed at key times. The goals were to learn about the experiences of adolescents and parents caring for adolescents with NF1 and to provide peer support for adolescents and parents of adolescents with NF1 through the social media platform. At baseline, adolescents were using social media more than their parents, and most adolescents and parents had not met/interacted with others with NF1 and felt isolated in their experience. They experienced improved awareness and quality of life | 1267
